After 6 years with Xolair; a 3-year withdrawal follow-up

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Bibtex

@article{21d15b7f66e94a76a1df283fd62b27ac,
title = "After 6 years with Xolair; a 3-year withdrawal follow-up",
abstract = "P>Background: This study reports the clinical and immunological state of patients 3 years after a 6-year period of Xolair treatment for severe allergic asthma. Methods: The patient's cat allergen sensitivity, measured as CD-sens, IgE and IgE- and IgG4 antibodies, was analysed and compared with asthma severity evaluated from FEV1 and a questionnaire. Results: Three years after treatment with Xolair was stopped, 12/18 patients reported improved or unchanged asthma compared with ongoing Xolair treatment. Most of the patients were in a stable clinical condition, 16/18 had not increased nightly asthma attacks and 14/18 little or no increase in medication. The CD-sens to cat was still significantly lower (P < 0.02) than untreated patients with allergic asthma and lower than expected from their serum IgE antibody levels. Conclusion: Most of the patients in this study had, still 3 years after closing of 6 years Xolair treatment, a surprisingly mild and stable asthma. Interestingly, the observed, considerable, downregulation of basophil allergen sensitivity, CD-sens, most likely representing mast cell allergen sensitivity, contributed to the clinical results.",
keywords = "omalizumab, CD-sens, IgE antibody",
author = "A. Nopp and Johansson, {S. G. O.} and J. Adedoyin and Jaro Ankerst and M. Palmqvist and H. Oman",
year = "2010",
doi = "10.1111/j.1398-9995.2009.02144.x",
language = "English",
volume = "65",
pages = "56--60",
journal = "Allergy",
issn = "1398-9995",
publisher = "Wiley-Blackwell",
number = "1",

}